Physician profile
Tierney Russell
NPI 1184324113
$1,813.43
in general payments reported to CMS, 2019-2025
15 companies · $673 in 2025
The $673 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $365 · 2024: $776 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,813.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $444.25 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $326.70 | 2024-2025 | Airsupra, Breztri |
| Pfizer INC. | $277.45 | 2023-2025 | |
| Lilly USA, LLC | $146.69 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $131.41 | 2023-2025 | Otezla, Repatha, Evenity |
| Dexcom, INC. | $119.34 | 2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Astellas Pharma US INC | $99.41 | 2023-2024 | Veozah |
| Glaxosmithkline, LLC. | $77.99 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $51.92 | 2025 | Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $46.39 | 2023-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.32 | 2023-2024 | Xifaxan, Trulance |
| Seqirus USA INC | $16.34 | 2024 | Flucelvax, Fluad |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.82 | 2024 | Jardiance |
| Antares Pharma, INC. | $14.78 | 2025 | Xyosted |
| Regeneron Healthcare Solutions, INC. | $14.62 | 2023 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tierney Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.